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The prevalence of obesity is increasing in many
countries all over the world.1 The health risks associ-
ated with obesity, such as type 2 diabetes, hypertension,
coronary artery disease, gallbladder disease, and arthri-
tis, form a serious public health problem for the years
to come if no effective strategies to prevent and treat it
are developed.1 Comprehensive weight management
programs, including a reduction of energy intake
through an energy-restricted diet and an increase in
energy expenditure through increased levels of physi-
cal activity in combination with a behavior modifica-
tion program, have been developed. In many cases such
programs lead to considerable short-term weight loss.
However, long-term maintenance of the reduced weight
often fails to occur. Current pharmacologic approaches
to the treatment of obesity focus on reinforcement of
these programs and they have been shown to improve
long-term weight maintenance success.2,3 The pharma-
cologic agents currently available for the management
of obesity (orlistat and sibutramine) are effective
through decreased nutrient absorption and appetite sup-
pression, respectively. The approach of increased
energy expenditure has been less well explored.
The peripheral sympathetic nervous system plays an
important role in the regulation of energy expenditure.4
Stimulation of sympathetic activity results in an
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increase of resting energy expenditure in humans,
which is mediated by β-adrenergic receptors.5 Both β1-
and β2-adrenergic receptors lead to thermogenesis on
stimulation.6,7 Obesity appears to be associated with a
blunted response to sympathetic stimulation that is
probably caused mainly by β2-adrenergic receptor mal-
function.7,8 However, treatment of obesity with the
classic nonselective or β2-selective agonists is not pos-
sible, because of the many unacceptable side effects of
these drugs.
The discovery of a third β-adrenergic receptor sub-
type in humans, which in animal models has been
shown to stimulate lipolysis in brown and white adi-
pose tissue and lead to thermogenesis in brown
adipocytes, has opened new possibilities for treatment
of human obesity by selective β3-adrenergic receptor
stimulation. In humans the presence of β3-adrenergic
receptor mRNA has been shown in brown and white
adipose tissue and the gall bladder, colon, stomach,
small intestine, prostate gland, and heart but not in
skeletal muscle or the liver, lung, kidney, thyroid, or
lymphocytes.9-12 One study has more recently provided
evidence for the presence of the β3-adrenergic receptor
protein in human gastrocnemius muscle and the right
atrium.13 Although most of the currently available β3-
adrenergic receptor agonists are only weak partial ago-
nists of the human β3-adrenergic receptor and usually
not very selective, a functional role for the β3-receptor
in adipocyte lipolysis has been suggested by studies in
isolated human omental and subcutaneous fat cells14,15
and in vivo in microdialysis studies with such ago-
nists.16-18 Because these drugs are not available for
intravenous or oral administration in humans, their ther-
mogenic efficacy is unknown. Indirect studies that used
combinations of different sympathomimetics and
blockers to dissect out the contribution of the β3-recep-
tor to human thermogenesis have yielded inconsistent
results.19-22
L-796568 [(R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)
ethyl]amino]ethyl]-phenyl]-4-[4-[4-(trifluoro-
methyl)phenyl]thiazol-2-yl]-benzenesulfonamide,
dihydrochloride] is a newly developed β3-adrenergic
receptor agonist with high affinity (concentration that
produces 50% of the maximum possible response
[EC50], 3.6 ± 2.2 nmol/L) and efficacy (94% ± 10% of
maximal cyclic adenosine monophosphate accumula-
tion by isoproterenol [INN, isoprenaline]) for the
cloned human β3-adrenergic receptor transfected in
Chinese hamster ovary cells.23 L-796568 is a weak par-
tial agonist at the human β1-receptor and β2-receptor,
with EC50 values of 4.8 and 2.4 µmol/L, respectively,
and efficacy of 25% of isoproterenol activity.23 Phase I
human studies showed that L-796568 was well toler-
ated in doses up to 1500 mg. Administration of L-
796568 therefore allows us to study, for the first time,
the effects of a specific human β3-adrenergic receptor
agonist on in vivo lipolysis and thermogenesis in
humans. This study was designed to investigate the
thermogenic efficacy of single oral doses of 250 and
1000 mg L-796568 in obese men.
METHODS
Subjects. Twelve healthy, nonsmoking male volunteers
between 18 and 45 years old (mean ± SD, 34.4 ± 5.8
years) were included in the study. All of the subjects had
maintained a stable weight (±4 kg) and had a body mass
index between 28 and 34 kg/m2 (mean ± SD, 30.7 ± 2.1
kg/m2). None of the volunteers had participated in an
organized weight loss program during the previous 3
months. All had normal blood pressure measurements (90
to 150 mm Hg systolic and 50 to 95 mm Hg diastolic
blood pressure) and resting heart rates (<90 beats/min).
Habitual heavy consumers of coffee (>4 cups per day)
were excluded. Current or anticipated use of any pre-
scription or nonprescription drugs was not allowed.
Experimental protocol. The study was a 2-center,
3-period, randomized, placebo-controlled, crossover
trial. In each period subjects received 250 mg L-
796568, 1000 mg L-796568, or placebo in a balanced
fashion. All drug supplies were provided as a “double
dummy,” so investigators and subjects were blinded to
the treatment regimen. A washout period of 6 to 8 days
between study periods allowed plasma levels of L-
796568 to dissipate. Prestudy procedures included a
medical history and a physical examination that
included vital signs, determination of body mass index,
measurement of thyroid function parameters, a safety
laboratory panel for blood and urine, and a 12-lead
electrocardiogram (ECG).
On the test days the subjects came to the laboratory
in the morning after an overnight fast. Urine was col-
lected for the safety panel. Subjects rested in a semire-
cumbent position, and a catheter was inserted into a
forearm vein of each subject for blood sampling (100
minutes before dosing). Continuous heart rate and
blood pressure monitoring was started, and heart rate
and blood pressure were registered at 65 and 20 min-
utes before dosing. At 10 minutes before dosing, blood
samples were taken for plasma catecholamine concen-
tration (heparinized tubes that contained glutathione),
plasma free fatty acids and glycerol concentration (eth-
ylenediaminetetra-acetic acid tubes), plasma potassium
(lithium-heparin tubes), and serum leptin concentration
(serum tubes), as well as for the safety laboratory panel.
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At 0 minutes before dosing, another blood sample was
obtained for free fatty acids and glycerol concentration
and for serum leptin concentration. After all blood was
drawn, the catheter was flushed with saline solution.
Ear temperature was determined at 60 minutes before
dosing. Energy expenditure was measured for 30 min-
utes, from 60 minutes before dosing to 30 minutes
before dosing, as a predose baseline.
After the baseline measurements, each subject was
given a single oral dose of the study drug (250 mg or
1000 mg L-796568 or placebo) with 240 ml water and
continued to fast and rest in a semisupine position for 4
hours. During this period, energy expenditure was mea-
sured during the last 20 minutes of each half hour. The
first 10 minutes of each half hour was used for either
blood sampling or calibration or both. Blood pressure
and heart rate continued to be monitored and were
recorded every 30 minutes. Blood samples for potassium,
free fatty acids, and glycerol were obtained at 1, 2, 3,
and 4 hours after dosing. Blood samples were obtained
1.5 and 4 hours after dosing for plasma catecholamines
and 4 hours after dosing for leptin. The catheter was
flushed with saline solution after each blood sample 
was drawn. Four hours after dosing, ear temperature was
measured and a 12-lead ECG was obtained.
Methods. Energy expenditure was determined by
indirect calorimetry with use of a ventilated hood sys-
tem. Flow through the hood was set at approximately
50 L/min and was measured with a dry gas meter
(Maastricht: Schlumberger, Dordrecht, The Nether-
lands; Copenhagen: Oxycon-beta, Mijnhardt, The
Netherlands). 
·
VO2 and 
·
VCO2 were determined every 15
seconds from flow through the hood and the difference
in oxygen (Maastricht: paramagnetic oxygen analyzer,
Servomex, Crowborough, United Kingdom; Copen-
hagen: Oxycon-beta) and carbon dioxide (Maastricht:
paramagnetic CO2 analyzer, Servomex; Copenhagen:
Oxycon-beta) concentrations between ingoing and out-
going air. Identical calibration procedures were used in
the two centers. Respiratory quotient was calculated as
·
VCO2/
·
VO2. Energy expenditure was calculated from 
·
VO2
and 
·
VCO2 with the abbreviated Weir formula.24
Blood pressure and heart rate were measured with a
semiautomated device (Maastricht: Omron 705 CP,
Hamburg, Germany; Copenhagen: digital blood pres-
sure meter model UA-743, A & D Company, Tokyo,
Japan). Heart rate monitoring was performed by means
of a 3-lead ECG monitor (Maastricht: Cardiolife,
Nikon-Kohden, Tokyo, Japan; Copenhagen: Diascope
2, model 211, Simonsen & Weel, Copenhagen, Den-
mark). The 12-lead ECG was registered by means of a
Cardiette Daedalus View H, H&C Medical Devices,
Cavareno, Italy (Maastricht), or a Microsmart MC,
Marquette Hellige, Freiburg, Germany (Copenhagen).
Analytic methods. Blood for serum leptin was allowed
to clot at least 30 minutes and was then centrifuged for
15 minutes at 1200g at room temperature. All other blood
samples were centrifuged immediately at 4°C for 15 min-
utes at 1200g except for the sample for potassium, which
was centrifuged at room temperature. Plasma and serum
were stored at –80°C until analysis.
Plasma free fatty acids,25 glycerol,26 potassium (direct
potentiometry with an ion-selective electrode), and serum
leptin27 were analyzed at the Department of Clinical
Chemistry, Academic Hospital of the Free University of
Brussels (Brussels, Belgium). Plasma catecholamine con-
centrations (norepinephrine and epinephrine) were ana-
lyzed at the Department of Human Biology in Maastricht
by HPLC with electrochemical detection by use of a kit
from Recipe (München, Germany).28
Data analysis. Data are presented as mean values ±
SD, unless stated otherwise. For all variables, mean val-
ues at baseline (ie, predose for each treatment period) and
at 4 hours after dosing were calculated. Within-treatment
changes from baseline to 4 hours after dosing were com-
puted by subtracting the baseline value from the 4-hour
postdose value [∆4-0 h]). In addition, mean energy expen-
diture during the 4-hour postdose period (mean 0-4 h)
and 1-hour peak values were calculated for energy expen-
diture (for each treatment the two 20-minute measure-
ments within each hour were averaged and the highest 1-
hour mean value was chosen as the 1-hour peak value).
The 3 treatments were compared by ANOVA for repeated
measures (baseline values, 4-hour postdose values, and
changes over the 4-hour postdose period [∆4-0 h]). In
case of a significant overall ANOVA outcome (P < .050),
post hoc comparisons between the 250- and 1000-mg
doses of L-796568 and placebo were performed by paired
t tests. Within-treatment differences between the 4-hour
postdose and baseline measurements were analyzed by
paired t tests. A P value <.050 was considered to be sta-
tistically significant.
RESULTS
L-796568 was generally well tolerated in this study.
Side effects were reported by 7 subjects, were of mild
to moderate intensity, and had disappeared within 24
hours. No tremor was reported. No significant changes
in safety laboratory parameters or urine composition
were found in any subjects during the course of the
study, except in 1 subject in whom low total cholesterol
was found that appeared to be unrelated to the drug. At
baseline there were no statistically significant differ-
ences for any of the variables among conditions.
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Table I. Values of all variables (mean ± SD) at baseline (0 h) and at 4 hours after dosing (4 h) and the change during
the 4-hour postdose period (∆4-0 h)
Variable and treatment 0 h 4 h ∆4-0 h
Energy expenditure (kJ/min)
Placebo 6.05 ± 0.55 6.14 ± 0.59 0.09 ± 0.36
250 mg 6.11 ± 0.53 6.16 ± 0.48 0.06 ± 0.21
1000 mg 5.97 ± 0.58 6.43 ± 0.52** 0.46 ± 0.31**
ANOVA P = .38 P < .050 P < .001
Ear temperature
Placebo 36.6°C ± 0.5°C 36.7°C ± 0.7°C 0.13°C ± 0.40°C
250 mg 36.5°C ± 0.4°C 36.7°C ± 0.6°C 0.15°C ± 0.48°C
1000 mg 36.4°C ± 0.5°C 36.8°C ± 0.5°C 0.33°C ± 0.22°C
ANOVA P = .35 P = .80 P = .19
Plasma free fatty acids (mmol/L)
Placebo 0.341 ± 0.115 0.542 ± 0.144 0.183 ± 0.138
250 mg 0.303 ± 0.123 0.585 ± 0.115 0.283 ± 0.166
1000 mg 0.327 ± 0.100 0.780 ± 0.185** 0.444 ± 0.224**
ANOVA P = .63 P < .001 P < .010
Plasma glycerol (µmol/L)
Placebo 48.0 ± 17.3 60.8 ± 17.9 11.6 ± 21.4
250 mg 41.1 ± 9.6 63.4 ± 13.8 23.1 ± 14.8*
1000 mg 41.4 ± 10.1 78.7 ± 20.7** 36.3 ± 19.6**
ANOVA P = .20 P < .001 P < .001
Respiratory quotient
Placebo 0.803 ± 0.062 0.793 ± 0.034 –0.010 ± 0.035
250 mg 0.834 ± 0.052 0.796 ± 0.027 –0.038 ± 0.034
1000 mg 0.818 ± 0.040 0.783 ± 0.015 –0.035 ± 0.040
ANOVA P = .26 P = .39 P = .08
Plasma potassium (mmol/L)
Placebo 4.01 ± 0.24 3.97 ± 0.21 –0.04 ± 0.14
250 mg 4.10 ± 0.28 3.87 ± 0.14 –0.23 ± 0.24
1000 mg 4.18 ± 0.59 3.94 ± 0.14 –0.24 ± 0.55
ANOVA P = .56 P = .22 P = .29
Heart rate (beats/min)
Placebo 62.8 ± 11.1 59.4 ± 12.5 –3.5 ± 7.1
250 mg 60.3 ± 8.1 62.0 ± 7.0 1.5 ± 5.7
1000 mg 61.2 ± 8.2 61.4 ± 9.0 –0.2 ± 4.4
ANOVA P = .43 P = .62 P = .14
Systolic blood pressure (mm Hg)
Placebo 128.6 ± 6.6 130.1 ± 12.6 1.1 ± 10.0
250 mg 132.4 ± 6.2 135.6 ± 12.2* 3.2 ± 8.6
1000 mg 126.8 ± 9.7 139.1 ± 13.0** 12.2 ± 14.2**
ANOVA P = .16 P < .050 P < .010
Diastolic blood pressure (mm Hg)
Placebo 82.9 ± 6.7 85.7 ± 7.6 2.6 ± 5.8
250 mg 85.5 ± 7.1 87.3 ± 10.0 1.8 ± 6.1
1000 mg 81.9 ± 6.8 88.8 ± 10.5 6.8 ± 8.6
ANOVA P = .12 P = .29 P = .13
Plasma norepinephrine (ng/L)
Placebo 262 ± 70 271 ± 92 9.0 ± 54.1
250 mg 258 ± 108 278 ± 113 20.5 ± 64.1
1000 mg 289 ± 90 324 ± 129 34.8 ± 114.5
ANOVA P = .29 P = .16 P = .69
Plasma epinephine (ng/L)
Placebo 28 ± 14 38 ± 20 9.8 ± 21.0
250 mg 27 ± 21 32 ± 19 4.9 ± 12.3
1000 mg 28 ± 14 30 ± 14 2.2 ± 17.9
ANOVA P = .97 P = .21 P = .43
Serum leptin (µg/L)
Placebo 12.6 ± 7.6 11.8 ± 6.7 –0.78 ± 1.61
250 mg 14.0 ± 7.4 12.8 ± 6.6 –1.18 ± 1.17
1000 mg 11.9 ± 6.7 11.0 ± 6.9 –0.87 ± 0.54
ANOVA P = .18 P = .10 P = .70
ANOVA P value refers to overall between-groups ANOVA outcome.
*P < .05, **P < .001, versus placebo (post hoc paired t tests).
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Thermogenic effects. The changes in energy expen-
diture from baseline during the 4-hour postdose period
are shown in Fig 1. At 4 hours after dosing, energy
expenditure was significantly different among the 3 con-
ditions (P < .05, between-treatments overall ANOVA;
Table I). Energy expenditure increased significantly
from baseline to 4 hours after dosing (by 0.46 ± 0.31
kJ/min, 7.8%) after the 1000-mg dose (P < .001, within-
treatment paired t test). No statistically significant
changes were found after the 250-mg dose (0.06 ± 0.21
kJ/min, 1.0%; P = .35, within-treatment paired t test) or
after placebo (0.09 ± 0.36 kJ/min, 1.5%; P = .41, within-
treatment paired t test). The changes differed signifi-
cantly among the 3 conditions (P < .001, between-treat-
ments overall ANOVA; P < .001 for 1000 mg versus
placebo; P = .67 for 250 mg versus placebo; Table I).
Comparison of the 1-hour peak energy expenditures or
mean energy expenditure during the period from base-
line to 4 hours after dosing among the 3 treatments did
not yield statistically significant differences (P = .32  for
1000 mg versus placebo; P = .88 for 250 mg versus
placebo; between-treatments overall ANOVA).
Ear temperature values at different time points are
shown in Table I. No statistically significant differences
were found at any time point, and the 4-hour postdose
changes did not differ among treatments (P = .19,
between-treatments overall ANOVA).
Metabolic effects. The plasma concentrations of free
fatty acids and glycerol showed a dose-dependent
increase during the 4-hour postdose period (Fig 2),
which differed statistically significantly among condi-
tions (P < .010 for ∆4-0 h, between-treatments overall
ANOVA). The changes after the 250-mg dose (0.283 ±
0.166 mmol/L for ∆4-0 h free fatty acids; 23 ± 15
µmol/L for ∆4-0 h glycerol) and after the 1000-mg dose
(0.444 ± 0.224 mmol/L for ∆4-0 h free fatty acids; 36
± 20 µmol/L for ∆4-0 h glycerol) differed significantly
from those after placebo (0.183 ± 0.138 mmol/L for
∆4-0 h free fatty acids; 12 ± 21 µmol/L for ∆4-0 h glyc-
erol) (∆4-0 h free fatty acids: P < .010, between-treat-
ments overall ANOVA; P = .09 for 250 mg versus
placebo; P < .005 for 1000 mg versus placebo; ∆4-0 h
glycerol: P < .001, between-treatments overall
ANOVA; P < .050 for 250 mg versus placebo; P < .005
for 1000 mg versus placebo; Table I).
The respiratory quotient at 4 hours after dosing did
not differ statistically significantly among treatments
(P = .39, between-treatments overall ANOVA; Table I),
although there was a tendency toward a reduction in the
respiratory quotient after the 250-mg (–0.038 ± 0.034)
and 1000-mg (–0.035 ± 0.040) doses compared with
placebo (–0.010 ± 0.035), but the difference among
treatments did not reach statistical significance (∆4-0
h respiratory quotient: P = .08, between-treatments
overall ANOVA). Plasma potassium concentrations
showed no statistically significant changes during any
of the treatments (Table I).
Cardiovascular effects. There were no statistically
significant differences in heart rate between the 3 treat-
ments at any time point, and the changes during the 4-
hour postdose period did not differ significantly. At 4
hours after dosing, there was a statistically significant
difference in systolic blood pressure among treatments
(P < .050, between-treatments overall ANOVA; Table
I). The increase in systolic blood pressure during the
4-hour postdose period was 1.5 ± 10.4 mm Hg after
placebo, 3.2 ± 8.7 mm Hg after 250 mg L-796568, and
12.2 ± 13.7 mm Hg after 1000 mg L-796568 (P < .005,
between-treatments ANOVA; P = .41 for 250 mg ver-
sus placebo; P < .010 for 1000 mg versus placebo;
Table I). No statistically significant differences in dia-
stolic blood pressure were observed during the study
period (Table I).
Hormonal effects. No differences in plasma norepi-
nephrine, epinephrine, or serum leptin concentrations
were found among treatments during the 4-hour study
period (Table I).
DISCUSSION
Despite the very clear role of β3-adrenergic recep-
tors in the regulation of energy expenditure in several
animal models, their importance in human thermogen-
esis has not yet been convincingly shown. Several β3-
adrenergic receptor agonists have been tested in
humans, but because of their poor selectivity and effi-
cacy, the results so far have not been convincing.29-32
In contrast to these compounds, L-796568 is both a
highly selective and a highly effective agonist of the
human β3-adrenergic receptor in vitro.23 This study
clearly showed that L-796568 also has lipolytic and
thermogenic activity in vivo after single-dose adminis-
tration to obese men. At 4 hours after administration,
the 1000-mg dose had increased energy expenditure by
about 8%. The time to peak plasma concentration of L-
796568 has been shown to be about 4 to 5 hours.33 In
this study the plasma concentration of L-796568 there-
fore probably had not reached its peak in all individu-
als after the 4-hour period, and a further thermogenic
effect by L-796568 after 4 hours is likely.
In vitro the EC50 of L-796568 for stimulation of the
human β3-adrenergic receptor was 3.6 nmol/L. The
EC50 values of L-796568 for human β1-adrenergic
receptor (4770 nmol/L) and β2-adrenergic receptor
stimulation (2405 nmol/L) were much higher than
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those for human β3-adrenergic receptor stimulation.23
In another study it was found that the peak plasma con-
centration of L-796568 was about 28.5 nmol/L after a
single 250-mg dose and about 89.4 nmol/L after a sin-
gle 1000-mg dose in lean healthy volunteers (Merck
Research Laboratories. Data on file). Both concentra-
tions were well above the EC50 of β3-adrenergic recep-
tor stimulation, and the highest concentration was still
>25-fold lower than the EC50 for β2-adrenergic recep-
tor stimulation and >50-fold lower than the EC50 forβ1-adrenergic receptor stimulation. However, a signifi-
cant contribution of β2- or β1-adrenergic receptor-medi-
ated stimulation cannot be fully excluded only on the
basis of comparisons with in vitro EC50 values. Tremor
and hypokalemia, indicators of β2-adrenergic receptor
stimulation, were not evident and it is unlikely that the
effects of L-796568 were the result of stimulation of
sympathetic nervous system activity because plasma
catecholamine concentrations did not change.
Several in vitro studies have shown that human sub-
cutaneous adipose tissue and especially omental adi-
pose tissue express functional β3-adrenergic recep-
tors.14,15 Microdialysis studies have shown that these
receptors are also functional in situ.16-18 This study con-
firms that systemic administration of a β3-adrenergic
receptor agonist is also capable of stimulating lipolysis
in vivo. In a recent study we showed that increased
plasma concentrations of free fatty acids induced ther-
mogenesis in lean and obese subjects in the absence of
stimulation by the sympathetic nervous system.33 It is
therefore conceivable that the thermogenic response
after L-796568 administration is caused by the β3-
adrenergic receptor-mediated stimulation of lipolysis
and does not involve any further β3-adrenergic recep-
tor-mediated effects.
Systolic blood pressure increased significantly after
L-796568. In the absence of an increase in heart rate,
this suggests increased contractility of the heart or an
increase in total peripheral resistance. However, dia-
stolic blood pressure did not increase significantly,
which does not support an increase in peripheral resis-
tance. Moreover, in vivo and in vitro experiments in
different animal species suggest a vasodilatory effect
Fig 1. Energy expenditure (mean ± SEM) after placebo
(squares), 250 mg L-796568 (circles), and 1000 mg L-796568
(triangles).
Fig 2. Mean ± SEM plasma free fatty acid concentrations
(FFA; A) and glycerol concentrations (B) after placebo
(squares), 250 mg L-796568 (circles), and 1000 mg L-796568
(triangles).
A
B
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of β3-adrenergic agonists.34 The presence of β3-adren-
ergic receptors in the human heart has been reported
for the right atrium13 and for the ventricular endomyo-
cardium.12 To date, the functional role of the atrial β3-
adrenergic receptors is unclear. Stimulation of the ven-
tricular β3-adrenergic receptors produces a negative
inotropic effect in animals and in human ventricular
endomyocardial biopsies.12,34 On the basis of these
findings, a role for the up-regulation of β3-adrenergic
receptors in human heart failure as a protection against
further myocyte damage has been proposed.34 How-
ever, a negative inotropic effect of stimulation of β3-
adrenergic receptors is not in line with the increase in
systolic blood pressure that was observed in this study.
On the basis of these data, an increased contractility of
the heart as a result of β1-adrenergic receptor stimula-
tion by L-796568 cannot be fully excluded. However,
the pattern of changes of the different variables after L-
796568 is not identical to that after specific β1- (or β2)-
adrenergic receptor stimulation.33
In conclusion, single-dose administration of 1000 mg
of the novel β3-adrenergic receptor agonist L-796568
increased lipolysis and energy expenditure in over-
weight men. This is the first study to show such an
effect of β3-adrenergic receptor agonists in humans,
without significant evidence for β2-adrenergic receptor
involvement. Involvement of β1-adrenergic receptor
stimulation could not be fully excluded but seems to be
unlikely in view of the higher EC50 for human β1-
adrenergic receptor stimulation than for human SYM-
BOLB3-adrenergic receptor stimulation in vitro and the
plasma concentrations likely to be present.
We thank Jos Stegen for his analysis of the plasma catecholamines.
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